Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00875238 · ClinicalTrials.gov registry record
Side Effects Involving the Heart in Women With Breast Cancer Receiving Doxorubicin and Trastuzumab
A clinical trial of Breast Cancer and Cardiac Toxicity, sponsored by Vanderbilt University.
- Completed
- Registry status
- 133
- Enrollment target
- 4
- Study locations
NCT00875238: Completed study of Breast Cancer and Cardiac Toxicity, sponsored by Vanderbilt University.
NCT00875238 is a study of Breast Cancer and Cardiac Toxicity that has completed, run by Vanderbilt University. The registered enrollment target is 133 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (95% lower). The trial reports 4 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00875238, a study of Breast Cancer and Cardiac Toxicity, has completed, sponsored by Vanderbilt University.
- COMPLETED
- Registry status
- 133 participants
- Enrollment target
- 4
- Study locations
Study Summary
RATIONALE: Studying samples of blood and tissue in the laboratory from women receiving doxorubicin and trastuzumab for breast cancer may help doctors learn more about changes that occur in DNA and identify biomarkers for increased risk of cardiac effects. PURPOSE: This clinical trial is studying side effects involving the heart in women with breast cancer receiving doxorubicin and trastuzumab.
Primary Outcome
change in cardiac function as measured by serial echocardiograms
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- OTHER questionnaire administration
- BIOLOGICAL trastuzumab
- GENETIC polymorphism analysis
- DRUG doxorubicin hydrochloride
Study Locations (4)
Tennessee
- Vanderbilt Heart One Hundred Oaks - Nashville
- MBCCOP - Meharry Medical College - Nashville - Nashville
- Vanderbilt-Ingram Cancer Center - Nashville
Kentucky
- University of Louisville James Graham Brown Cancer Center - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 133 participants |
| Start Date | 2008-06 |
| Est. Completion | 2015-03 |
What the finished NCT00875238 record still lists
NCT00875238 is an observational study that tracks outcomes without assigning an intervention. The registered 133 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (95% lower).
The record links to 3 conditions, with Breast Cancer appearing as the primary indexed condition, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT00875238 reports a single indexed study location in Tennessee, Kentucky.
Frequently Asked Questions
What is clinical trial NCT00875238 about?
NCT00875238 is a clinical study titled "Side Effects Involving the Heart in Women With Breast Cancer Receiving Doxorubicin and Trastuzumab". RATIONALE: Studying samples of blood and tissue in the laboratory from women receiving doxorubicin and trastuzumab for breast cancer may help doctors learn more about changes that occur in DNA and identify biomarkers for increased risk of cardiac effects. PURPOSE: This clinical trial is studying si...
What is the current status of trial NCT00875238?
This trial is currently completed. The enrollment target is 133 participants. The study started on 2008-06. Estimated completion is 2015-03.
What conditions does trial NCT00875238 study?
This clinical trial studies the following conditions: Breast Cancer, Cardiac Toxicity, Cardiovascular Complications.
What interventions are being tested in trial NCT00875238?
The interventions under investigation include: laboratory biomarker analysis (OTHER), questionnaire administration (OTHER), trastuzumab (BIOLOGICAL), polymorphism analysis (GENETIC), doxorubicin hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00875238?
This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00875238 being conducted?
This trial has 4 study locations across Kentucky, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00875238's enrollment target sits among peer trials
133 484th of 1224 higher than 741 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Surviving Daily Life
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
UNC Pleural Fluid Registry
RECRUITING
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04276870 · 133 participants · Phase 2
Orphan Indications for CD19 Redirected Autologous T Cells
- NCT04671771 · 133 participants · NA
A Study to Evaluate the Safety and Effectiveness of the InnAVasc Arteriovenous Graft for Hemodialysis Access in Patients With End-Stage Renal Disease
- NCT05610085 · 133 participants · Phase 2
A Dose Escalation Study of Levetiracetam in the Treatment of Neonatal Seizures
- NCT06206486 · 133 participants
The Gut Microbiome and Serum Metabolites As a Biological Mechanism Underlying Pain in Kidney Transplantation
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia